Article
London - Researchers in Australia reporting on an immunotherapy trial with vaccinia viral melanoma cell lysates in patients with stage IIb and III melanoma say that finding an effective adjuvant treatment for melanoma is proving to be a challenge.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.